Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications

Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with del(5q) being the most prevalent. Since its f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2024-06, Vol.112 (6), p.860-869
Hauptverfasser:	Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Capodanno, Isabella, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bone marrow Chromosome 5 Chromosome Deletion Chromosomes, Human, Pair 5 - genetics common deleted regions Cytogenetics Disease resistance Hemopoiesis Humans lenalidomide Lenalidomide - therapeutic use Leukemia MDS‐5q Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - etiology Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - therapy myeloid neoplasm Phenotypes Thrombocytosis TP53 mutation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!